Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

Chronic hand eczema. | Image Credit: IIIRusya - stock.adobe.com
Chronic Hand Eczema Has Significant Impacts on Patients' Lives, Survey Reveals

April 22nd 2025

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Raj Chovatiya, MD, PhD, MSCI
Addressing Unmet Needs, Emerging Treatment for Atopic Dermatitis: Raj Chovatiya, MD, PhD

April 9th 2025

Migrant Populations. | Image Credit: wladimir1804 - stock.adobe.com
Review Explores Skin Health Risks of US Migrant Populations

April 9th 2025

Research presented. | Image Credit: somneuk - stock.adobe.com
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost

April 8th 2025

Crystal Aguh, MD, FAAD
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches

March 28th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives
Continuing Medical Education
View All
April 26th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
April 26th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

dermatology exam | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
May 17th 2024

Study Reveals Decline in Inpatient Dermatology Services and Urgent Need for Strategic Support

Skylar Jeremias
A recent study found significant regional disparities and a decline in inpatient dermatology encounters and providers across the US from 2013 to 2019, highlighting the need for increased support and improved access to specialized dermatologic care.
Patient scratching atopic dermatitis (AD) on hand | Image Credit: Ольга Тернавская - stock.adobe.com
May 14th 2024

Patients With AD Prioritize Itch Control in Treatment Preferences

Brooke McCormick
A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching.
machine learning | Image credit: WrightStudio - stock.adobe.com
May 11th 2024

Machine Learning Model Could Predict Hidradenitis Suppurativa Diagnosis

Skylar Jeremias
A recent study applied machine learning to medical and pharmacy claims data to develop a model for predicting hidradenitis suppurativa (HS) diagnosis, highlighting the potential for improved understanding of HS underdiagnosis on a health care system level.
acne scarring | Image credit: frank29052515 - stock.adobe.com
May 4th 2024

Combining Surgical, Nonsurgical Approaches Holds Promise for Treating Facial Acne Scars

Skylar Jeremias
According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.
climate change | Image credit: lamyai - stock.adobe.com
May 3rd 2024

Review Identifies Multiple Climate Change Factors Influencing Skin Cancer Rates

Skylar Jeremias
A literature review has found that ultraviolet radiation, rising temperature, and air pollution could be possible climate-related influences on skin cancer rates.
red light therapy | Image credit: Space_Cat - stock.adobe.com
April 22nd 2024

Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT

Skylar Jeremias
A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
dr monica li
April 16th 2024

Dr Monica Li Explains Efficacy, Safety Differences Between Different Microneedling Techniques

Pearl Steinzor Brooke McCormick
Monica Li, MD, medical and cosmetic dermatologist, explained the efficacy and safety differences between radiofrequency microneedling and traditional microneedling.
syringe and vial | Image credit: PhotobyTawat - stock.adobe.com
April 11th 2024

Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52

Skylar Jeremias
In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
dr robert sidbury
April 9th 2024

Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice

Pearl Steinzor Brooke McCormick
Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.
doctor talking to patient | Image credit: Suteren Studio - stock.adobe.com
April 5th 2024

Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps

Skylar Jeremias
Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
dr monica li
April 2nd 2024

Dr Monica Li Lists Microneedling Considerations, Precautions

Pearl Steinzor Brooke McCormick
Monica Li, MD, medical and cosmetic dermatologist, listed microneedling considerations and precautions so that providers can safely implement the procedure.
man's hands with atopic dermatitis | Image Credit: Ольга Тернавская - stock.adobe.com
March 20th 2024

Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

Brooke McCormick
These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
little boy crying at school while group of students run away | Image Credit: Rido - stock.adobe.com
March 18th 2024

Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

Brooke McCormick
Posters presented showed that patients with vitiligo have a heightened risk of stigma and subsequent mental health issues.
Patient using phone | Image Credit: guteksk7 - stock.adobe.com
March 17th 2024

AI Dermatology Mobile Apps Have Critical Efficacy, Safety Gaps, Review Says

Brooke McCormick
This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.
Shawn Kwatra, MD, dermatologist, John Hopkins University
March 15th 2024

Dr Shawn Kwatra Shares Efficacy, Safety Data of Nemolizumab in Patients With PN

Pearl Steinzor
Shawn Kwatra, MD, dermatologist, John Hopkins University, discusses late breaking study results on the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis (PN).
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
March 15th 2024

Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

Pearl Steinzor
Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, shares 16-week safety and efficacy data from the FRONTIER 2 clinical trial on JNJ-2113 for patients with moderate to severe plaque psoriasis.
Martin Dahl, PhD, senior vice president, AnaptysBio
March 11th 2024

Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

Pearl Steinzor
AnaptysBio's senior vice president of research, Martin Dahl, PhD, discusses therapeutic strategies and pathophysiological approaches to treating patients with atopic dermatitis (AD).
Jeff Stark, MD, vice president, head of medical immunology, UCB.
March 11th 2024

Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

Pearl Steinzor
Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).
Books with stethoscope | Image credit: ronstik - stock.adobe.com
March 11th 2024

Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

Julia Bonavitacola
Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Hands with atopic dermatitis | Image credit: InfiniteStudio - stock.adobe.com
March 11th 2024

Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

Julia Bonavitacola
Presented posters showed that moderate to severe atopic dermatitis (AD) in skin of color can be treated with either biologic or topical therapies.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
March 10th 2024

Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

Pearl Steinzor
In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.
Woman with hidradenitis suppurativa under arm | Image credit: Lea - stock.adobe.com
March 10th 2024

Management of HS Requires Both Coordination, Communication Between Patients and Providers

Julia Bonavitacola
Treating pediatric and adult patients with hidradenitis suppurativa (HS) who are in socioeconomically underserved areas can be done through collaboration with the patient, their family, and other clinicians in the field.
Vitiligo in light skin | Image credit: shurkin_son - stock.adobe.com
March 10th 2024

Skin Tone Bias Persists in Google Searches for Vitiligo

Julia Bonavitacola
Pictures of darker skin with vitiligo make up more than three-quarters of Google searches for pictures of vitiligo, according to posters.
Monica Li, MD, University of British Columbia
March 10th 2024

Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

Pearl Steinzor
Monica Li, MD, medical and cosmetic dermatologist and clinical assistant professor, University of British Columbia, discusses how microneedling can address both aesthetic and medical dermatological needs across different skin types.
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
March 9th 2024

Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

Pearl Steinzor
Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses what makes a dermatology practice successful and the challenges that come with running a practice.
Older adult with atopic dermatitis | Image credit: berna_namoglu - stock.adobe.com
March 9th 2024

Atopic Dermatitis in Adults: Challenges and Treatment Strategies

Julia Bonavitacola
A session held at the American Academy of Dermatology Annual Meeting 2024 highlighted the ways in which atopic dermatitis can be treated and addressed in adults and older adults.
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
March 8th 2024

Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

Pearl Steinzor
There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.
Man applying cream to rash | Image credit: Olga - stock.adobe.com
March 8th 2024

Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

Julia Bonavitacola
A physician-reported outcomes survey found that physicians switched to ruxolitinib cream due to lack of effectiveness with previous atopic dermatitis (AD) treatments, and an analysis of claims data revealed the cream reduced the need for other treatments.
FDA Approved - chrisdorney - stock.adobe.com
February 16th 2024

FDA Grants Accelerated Approval to Lifileucel, First Cellular Therapy for Advanced Melanoma

Rose McNulty
Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.
ICYMI: Highlights From Fall Clinical Dermatology Conference 2023
January 2nd 2024

ICYMI: Highlights From Fall Clinical Dermatology Conference 2023

Cameron Santoro
The 2023 Fall Clinical Dermatology conference featured research on treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo.
<12345678
...
10>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo